Fabio Mangiacapra1, Iginio Colaiori2, Elisabetta Ricottini2, Francesco Balducci2, Antonio Creta2, Chiara Demartini2, Giorgio Minotti3, Germano Di Sciascio2. 1. Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Via Álvaro del Portillo, 200, 00128, Rome, Italy. f.mangiacapra@unicampus.it. 2. Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Via Álvaro del Portillo, 200, 00128, Rome, Italy. 3. Unit of Drug Science, Department of Medicine, Campus Bio-Medico University, Rome, Italy.
Abstract
AIMS: Data from experimental studies suggest that the f current-inhibitor ivabradine may reduce oxidative stress and improve endothelial function. We aimed to evaluate the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). METHODS AND RESULTS: At least 30 days after PCI, 70 patients were randomized (T0) to receive ivabradine 5 mg twice daily (ivabradine group, n = 36) or to continue with standard medical therapy (control group, n = 34). After 4 weeks (T1), ivabradine dose was adjusted up to 7.5 mg twice daily in patients with heart rate (HR) at rest >60 bpm, and thereafter continued for additional 4 weeks (T2). At all timings, brachial artery reactivity was assessed by flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD). No significant differences were observed at T0 between ivabradine and control groups in terms of HR (68.0 ± 6.4 vs. 67.6 ± 6.4 bpm; p = 0.803), FMD (8.7 ± 4.9 vs. 8.0 ± 5.5 %; p = 0.577) and NMD (12.7 ± 6.7 vs. 13.3 ± 6.2 %; p = 0.715). Over the study period, a significant reduction of HR (65.2 ± 5.9 bpm at T1, 62.2 ± 5.7 bpm at T2; p < 0.001), and improvement of FMD (12.2 ± 6.2 % at T1, 15.0 ± 7.7 % at T2; p < 0.001) and NMD (16.6 ± 10.4 % at T1, 17.7 ± 10.8 at T2; p < 0.001) were observed in the ivabradine group, while no significant changes were observed in the control group. In the ivabradine group, a moderate negative correlation was observed between the HR variation and FMD variation from T1 to T3 (r = -0.448; p = 0.006). CONCLUSIONS: In patients with CAD undergoing complete revascularization with PCI, addition ofivabradine to the standard medical therapy produces a significant improvement in endothelial function. This effect seems to be related to HR reduction. ClinicalTrials.gov number, NCT02681978.
RCT Entities:
AIMS: Data from experimental studies suggest that the f current-inhibitor ivabradine may reduce oxidative stress and improve endothelial function. We aimed to evaluate the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). METHODS AND RESULTS: At least 30 days after PCI, 70 patients were randomized (T0) to receive ivabradine 5 mg twice daily (ivabradine group, n = 36) or to continue with standard medical therapy (control group, n = 34). After 4 weeks (T1), ivabradine dose was adjusted up to 7.5 mg twice daily in patients with heart rate (HR) at rest >60 bpm, and thereafter continued for additional 4 weeks (T2). At all timings, brachial artery reactivity was assessed by flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD). No significant differences were observed at T0 between ivabradine and control groups in terms of HR (68.0 ± 6.4 vs. 67.6 ± 6.4 bpm; p = 0.803), FMD (8.7 ± 4.9 vs. 8.0 ± 5.5 %; p = 0.577) and NMD (12.7 ± 6.7 vs. 13.3 ± 6.2 %; p = 0.715). Over the study period, a significant reduction of HR (65.2 ± 5.9 bpm at T1, 62.2 ± 5.7 bpm at T2; p < 0.001), and improvement of FMD (12.2 ± 6.2 % at T1, 15.0 ± 7.7 % at T2; p < 0.001) and NMD (16.6 ± 10.4 % at T1, 17.7 ± 10.8 at T2; p < 0.001) were observed in the ivabradine group, while no significant changes were observed in the control group. In the ivabradine group, a moderate negative correlation was observed between the HR variation and FMD variation from T1 to T3 (r = -0.448; p = 0.006). CONCLUSIONS: In patients with CAD undergoing complete revascularization with PCI, addition of ivabradine to the standard medical therapy produces a significant improvement in endothelial function. This effect seems to be related to HR reduction. ClinicalTrials.gov number, NCT02681978.
Authors: Florian Custodis; Stephan H Schirmer; Magnus Baumhäkel; Gerd Heusch; Michael Böhm; Ulrich Laufs Journal: J Am Coll Cardiol Date: 2010-12-07 Impact factor: 24.094
Authors: Ulrich Fischer-Rasokat; Jörg Honold; Denise Lochmann; Sebastian Wolter; Christoph Liebetrau; Stephan Fichtlscherer; Helge Möllmann; Ioakim Spyridopoulos; Christian W Hamm Journal: Clin Res Cardiol Date: 2015-12-19 Impact factor: 5.460
Authors: Kevin S Heffernan; Ramya Suryadevara; Eshan A Patvardhan; Paula Mooney; Richard H Karas; Jeffrey T Kuvin Journal: Clin Cardiol Date: 2011-01 Impact factor: 2.882
Authors: Rasmus Rivinius; Matthias Helmschrott; Arjang Ruhparwar; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Philipp Ehlermann; Hugo A Katus; Andreas O Doesch Journal: Clin Res Cardiol Date: 2017-11-02 Impact factor: 5.460
Authors: Juan Carlos Kaski; Steffen Gloekler; Roberto Ferrari; Kim Fox; Bernard I Lévy; Michel Komajda; Panos Vardas; Paolo G Camici Journal: Open Heart Date: 2018-03-09
Authors: Rasmus Rivinius; Matthias Helmschrott; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Hugo A Katus; Philipp Ehlermann Journal: Clin Res Cardiol Date: 2020-06-22 Impact factor: 5.460